Asia
Jiangsu Lianhuan Pharmaceutical's Three Drugs Win Pre-Bids Under China Procurement Program
Jiangsu Lianhuan Pharmaceutical (SHA:600513) and subsidiary Xinxiang Changle Pharmaceutical's three products won pre-bids under China's drug procurement system, according to a Wednesday filing with the Shanghai Stock Exchange.The drugs involved include azilsartan medoxomil for hypertension, bumetanide injection for severe fluid retention or edema, and vitamin B6 injection.Procurement for the drugs under the program will be valid through Dec. 31, 2029.In 2025, azilsartan sales reached 1.2 million yuan, while its bumetanide injection attained 502,249 yuan in sales, and its vitamin B injection saw sales of 711,600 yuan.
SHA:600513
